ATAZANAVIR IN BASIC ANTIRETROVIRAL THERAPY REGIMENS: A REVIEW OF CONVINCING DATA


Cite item

Full Text

Abstract

The paper analyzes current Russian and international guidelines for the choice of first-line antiretroviral therapy (ARVT) regimens for previously untreated HIV-infected patients. It reviews the convincing data obtained from large-scale trials of the efficacy and safety of ritonavir-boosted atazanavir, which have served as a basis for this drug to be included into the basic regimens of starting therapy for HIV infection. The paper discusses the advantages of atazanavir in terms of efficacy, safety, tolerability, and easiness-to-use, which may be considered as a rationale for its inclusion into the basic first-line ARVT regimens in our country.

Full Text

Restricted Access

About the authors

S. L MAKSIMOV

Moscow University of Medicine and Dentistry

References

  1. ФГУЗ Федеральный центр гигиены и эпидемиологии Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека. http://www. fcgsen.ru/5/arhiv.htm
  2. СПИД в России: минус 50 тыс. ежегодно. Свободная пресса. 11 апреля 2011 г. http://svpressa.ru/society/ ar ticle/41027
  3. ВИЧ-инфекция и СПИД: Клинические рекомендации / Под ред. В.В. Покровского. М.: ГЭОТАР-Медиа; 2010.
  4. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach. 2010 revision. http://whqlibdoc.who.int/ publications/2010/9789241599764_eng.pdf
  5. Clinical management and treatment of HIV-infected adults in Europe, EACS Guidelines, Version 5.4, 2009. http://www. europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/1_treatment_of_hiv_infected_adults.pdf
  6. Thompson M.A., Aberg J.A., Cahn P. et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. J.A.M.A. 2010; 304 (3): 321-333.
  7. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services (DHHS). January 10, 2011. http://www. aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
  8. Mallolas J., Blanco J.L., Pich J. et al. A randomized trial comparing the efficacy and tolerability of two HAART strategies at two years in antiretroviral naïve patients. Rev. Clin. Esp. 2007; 207 (9): 427-432.
  9. MacArthur R.D., Novak R.M., Peng G. et al. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial. Lancet 2006; 368 (9553): 2125-2135.
  10. Bartlett J.A., Fath M.J., Demasi R. et al. An updated systematic overview of triple combination therapy in antiretroviralnaïve HIV-infected adults. AIDS 2006; 20 (16): 2051-2064.
  11. Хоффман К., Рокштро Ю.К. Лечение ВИЧ-инфекции 2009. - М.: Р. Валент, 2010: 648.
  12. Walmsley S., Bernstein B., King M. et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV-infection. N. Engl. J. Med. 2002; 346 (26): 2039-2046.
  13. Molina J.M., Podsadecki T.J., Johnson M.A. et al. A LPV/ ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks. AIDS Res. Hum. Retroviruses 2007; 23: 1505-1514.
  14. Gathe J., Silva B.A., Cohen D.E. et al. A once-daily LPV/ ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviralnaive subjects through 48 weeks. J. Acquir. Immune Defic Syndr. 2009. 15; 50 (5): 474-481.
  15. Colonno R., Rose R., McLaren C. et al. Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens. J. Infect. Dis. 2004; 189 (10): 1802-1810.
  16. Koh Y., Nakata H., Maeda K. et al. Novel bistetrahydrofuranylurethane-containing nonpeptidic protease inhibitor UIC-94017 (TMC114) with potent activity against multi-PI-resistant HIV in vitro. Antimicrob Agents Chemother. 2003; 47: 3123-3129.
  17. Molina J.M., Andrade-Villanueva J., Echevarria J. et al. Once-daily atazanavir/ritonavir versus twice-daily LPV/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008; 372: 646-655.
  18. Ortiz R., Dejesus E., Khanlou H. et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 2008; 22 (12): 1389-1397.
  19. Malan D.R., Krantz E., David N. et al. Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviralnaive patients. J. Acquir. Immune Defic Syndr. 2008; 47 (2): 161-167.
  20. European Medicines Agency. REYATAZ: summary of product characteristics. http://www.ema.europa.eu/ humandocs/PDFs/EPAR/reyataz/586503en6.pdf
  21. Кравченко А.В. Ингибитор протеазы ВИЧ дарунавир в схемах антиретровирусной терапии первой линии. Фарматека 2009; 19: 25-30.
  22. Molina J.M., Andrade-Villanueva J. et al. Once-daily atazanavir/ ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J. Acquir. Immune Defic Syndr. 2010; 53 (3): 323-332.
  23. Daar E.S., Tierney C., Fischl M.A. et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann. Int. Med. 2011; 154 (7): 445-456.
  24. Squires K.E., Johnson M., Yang R. et al. Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study. J. Antimicrob. Chemother. 2011; 66 (2): 363-370.
  25. Currier J., Averitt B.D., Hagins D. et al. Sex-based outcomes of darunavir/ritonavir therapy: a single-group trial. Ann. Int. Med. 2010; 153: 349-357.
  26. Roberts K.J., Mann T. Barriers to antiretroviral medication adherence in HIV-infected women. AIDS Care 2000; 12: 377-386.
  27. Malan N., Su J., Mancini M. et al. Gastrointestinal tolerability and quality of life in antiretroviral-naïve HIV-1-infected patients: data from the CASTLE study. AIDS Care 2010; 22 (6): 677-686.
  28. Sax P., Tierney C., Collier A. et al. ACTG 5202: shorter time to virologic failure (VF) with abacavir/lamivudine (ABC/3TC) than tenofovir/emtricitabine (TDF/FTC) as part of combination therapy in treatment-naïve subjects with screening HIV RNA ≥100,000 c/mL. 17th International AIDS Conference. Mexico City. 2008. Abstract THAB0303.
  29. Pappa K., Hernandez J., Ha B. et al. Abacavir/lamivudine (ABC/3TC) shows robust virologic responses in ART-naïve patients for baseline (BL) viral loads (VL) of ≥ 100,000c/ mL and <100,000c/mL by endpoint used in ACTG5202. 17th International AIDS Conference. Mexico City. 2008. Abstract THAB0304.
  30. Soriano V., Arastéh K., Migrone H. et al. Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN. Trial. Antivir. Ther. 2011; 16 (3): 339-348.
  31. Puls R.L., Srasuebkul P., Petoumenos K. et al. Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study. Clin. Infect. Dis. 2010; 51 (7): 855-864.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies